CD8+ lymphocytes, and high expression of PD-L1 and low infiltration of CD8+ lymphocytes were independently associated with poor prognosis in cancer patients. 5 These findings indicate that an imbalance between the cytotoxic (CD8) and tolerogenic (PD-L1) tumor microenvironment can be an immunological parameter to evaluate the prognosis of malignancies.
Thus, expression of PD-L1 and infiltration of CD8+ lymphocytes can be a fine biomarker for many types of malignancies. However, partly due to the rarity of the disease, these molecular markers have not been tested in medulloblastoma so far. In the present study, we examined the expression of PD-L1 and infiltration of CD3+ and CD8+ lymphocytes with immunohistochemical analysis, and evaluated their correlation with the prognosis of patients with medulloblastoma.
Methods

Medulloblastoma Cell Lines and Cell Culturing
Two human medulloblastoma cell lines, D283 Med (HTB-185) and Daoy (HTB-186), were purchased from American Type Culture Collection. All cell lines were established in culture prior to experimentation. Medulloblastoma cell lines were maintained at 37°C, 95% room air, and 5% CO 2 , in DMEM supplemented with 10% fetal bovine serum and 5% penicillin-streptomycin (100 U/ml penicillin, 100 mg/ml streptomycin). Cell lines were cultured, grown to approximately 80% confluence, washed in phosphate-buffered saline, and then trypsinized. Cells were subsequently centrifuged, resuspended in serum-free and antibiotic-free DMEM, and counted using a hemocytometer after staining with Trypan blue.
Patient Population and Tumor Specimens
Formalin-fixed, paraffin-embedded specimens were obtained in 16 patients who underwent primary surgery for medulloblastoma at Kyoto University Hospital between 1987 and 2009 (Table 1) . Clinical and pathological characteristics were collected from their medical records and telephone interviews, including age, sex, day of operation, radiation dosage and schedule, chemotherapy regimens, Chang's criteria, Ki-67 index, and survival. After surgery, all patients received radiotherapy and 14 received chemotherapy. The study was approved by the ethics committee of the Kyoto University Hospital.
Immunohistochemical Investigation
Formalin-fixed, paraffin-embedded specimens were deparaffinized in xylene and dehydrated in ethanol (99%, 90%, 80%, and 70%). For antigen retrieval of PD-L1, CD3, and CD8, the specimens were boiled in Tris-EDTA buffer (pH 9.0) by microwaves. To block endogenous peroxidase activity, the tissues were treated with 100% methanol containing 0.3% H 2 O 2 . Nonspecific binding of IgG was blocked using normal goat serum (Vector). The specimens were incubated with polyclonal rabbit anti-human PD-L1 antibody (LSBio: LS-B480); monoclonal rabbit anti-human CD3 antibody (Abcam); monoclonal mouse anti-human CD8 antibody (Abcam); monoclonal mouse anti-CTNNB1 antibody (BD Transduction Laboratories: ab610154); polyclonal rabbit anti-human SFRP1 (Abcam: ab4193); polyclonal rabbit anti-human NPR3 antibody (Abcam: ab37617); and polyclonal rabbit anti-human KCNA antibody (Abcam: ab32433) overnight at 4°C. Then the sections were incubated with goat anti-mouse and anti-rabbit secondary antibody (EnVision+ Dual Link System-HRP, Dako). Signals were generated by incubation with 3,3′-diaminobenzidine (Vector). Specimens were counterstained with hematoxylin and observed under a microscope. A section of normal placenta tissue was used as positive control.
Evaluation of Immunohistochemical Staining
The expression of PD-L1 was evaluated according to the intensity of the staining. We scored the findings as follows: 0, negative; 1, very weak expression; 2, moderate expression; and 3, strongest expression. The scores of 0 or 1 were defined as the low-expression group, and the scores of 2 or 3 were defined as the high-expression group. Two independent observers examined the immunohistochemical slides without any prior information regarding the clinical history of the patients. To objectively validate the assessment, we measured the intensity of the staining by using ImageJ software. The red-green-blue (RGB) method was used, and red color intensity was calculated in the region of interest in the slides with higher magnification (×400). 21 Five regions of interest (100 × 100 square pixels for each) were randomly selected in the nucleus area, and a mean pixel intensity value was used to quantitatively assess the staining intensity. The pixel intensity values ranged from 0 to 255, wherein 0 represents the darkest shade of the color and 255 represents the lightest shade of the color as standard. We set a cutoff pixel intensity value of 130, and a mean pixel intensity of > 130 was regarded as low expression.
The infiltration of CD3+ lymphocyte and CD8+ lymphocyte was evaluated according to counts of the number of cells after examination of the slides by using at least 3 different high-power fields (maximum, ×40 objective and ×10 eyepiece). Two independent observers examined the specimens by using the same method as above. The number of cells that stained positively for CD3 and CD8 was recorded. The result was interpreted as low infiltration when there were ≤ 5 cells per 3 fields, and as high infiltration when there were > 5 cells per 3 fields.
Molecular Subtypes
Molecular subtypes were determined by immunohistochemical studies because staining for DKK1 (WNT), SFRP1 (SHH), NPR3 (Group 3), and KCNA1 (Group 4) has been shown to reliably and uniquely classify formalin-fixed medulloblastomas in approximately 98% of patients. observed in 9 cases (56.3%), and low expression (score of 0 or 1) was observed in 7 (43.8%) cases (representative cases are shown in Fig. 1 ). Quantitative assessment of intensity of staining with a mean pixel intensity value was in complete agreement with the qualitative assessment: all of the high-expression cases showed a mean pixel intensity of ≤ 130 and all of the low-expression cases showed a mean pixel intensity of > 130. Tumor-infiltrating CD3+ and CD8+ lymphocytes were also examined. High infiltration of CD3+ lymphocytes was observed in 7 (43.8%) cases and high infiltration of CD8+ lymphocytes was observed in 6 (37.5%) cases (representative cases are shown in Fig. 1 ).
Correlation Between PD-L1, CD8, and CD3 Expressions and Clinical Characteristics
The average age at diagnosis for the 16 patients was 13.5 years (range 2-43 years). The mean follow-up period was 79.8 months (range 7.2-171.0 months), and 7 (43.8%) patients died of the disease (Table 1) . Clinical characteristics were compared according to the expression of PD-L1, CD8, or CD3. There was no significant difference of age, sex, Chang's criteria, Ki-67, and molecular subtypes (WNT, SHH, Group 3, and Group 4) according to the expression of these markers.
High PD-L1 and low CD8 Expressions: Correlation With Poor Progression-Free Survival and Overall Survival
The Kaplan-Meier survival curve demonstrated that both the progression-free survival (PFS) and overall survival (OS) in patients with high PD-L1 expression was worse than in those with low expression ( Fig. 2A and B) . The log-rank test showed marginally significant difference (p < 0.1) in both PFS (p = 0.076) and OS (p = 0.099). Seven of 9 specimens with high PD-L1 expression showed low infiltration of CD8+ lymphocytes, and 4 of 7 specimens with low PD-L1 expression showed high infiltration of CD8+ lymphocytes. Patients with high infiltration of CD8+ lymphocytes showed better survival than those with low CD8 expression, although it was not statistically significant ( Fig. 2C and D) . Similar survival trends were observed according to infiltrations of CD3+ lymphocytes (Fig. 2E and F) .
Of note, the combination of PD-L1 expression and CD8+ lymphocyte infiltration improved the risk stratification: patients with high PD-L1 expression and low CD8+ lymphocyte infiltration had a significantly worse prognosis than the other patients for both PFS (p = 0.0048) and OS (p = 0.010) (Fig. 3) . Stratified analysis using pediatric cases 16 years of age and younger also showed a significant difference (p = 0.0088 for PFS and p = 0.0276 for OS). On the other hand, Chang's criteria or Ki-67 index was not significantly associated with PFS or OS. Clinical and other pathological characteristics including Chang's criteria, Ki-67 index, and molecular subtypes (WNT, SHH, Group 3, and Group 4) were not different between patients with high PD-L1 expression and low CD8+ lymphocyte infiltration and the other patients, although age at onset was older in patients with high PD-L1 expression and low CD8+ lymphocyte infiltration (Table 1) . 
Discussion
Our data demonstrated that high PD-L1 expression was associated with lower CD8+ lymphocyte infiltration and worse prognosis in medulloblastoma. Infiltrations of CD3+ lymphocytes did not show a strong correlation either with PD-L1 or the prognosis of patients with medulloblastoma. These findings suggest that PD-L1 expressed on medulloblastoma may shift the balance of T lymphocytes (CD3+) into lower cytotoxic (CD8+) lymphocyte and higher regulatory T lymphocytes, leading to tumor progression. Interestingly, the combination of PD-L1 and CD8 assessment was more accurate in distinguishing patients with good prognosis from those with poor prognosis.
Nearly half of the patients showed high PD-L1 expression and low CD8+ lymphocyte infiltration, and they had a 5-year survival rate of as low as 15%. In contrast, the other half of patients had a 5-year survival rate of approximately 90%. These findings suggest that immunohistochemical analysis of PD-L1 and CD8, which reflect an antitumor immune microenvironment, could be a good biomarker for medulloblastoma, as is the case in other cancers. 5, 18 Considering that the shortest 5-year survival stratified by a single genetic alteration is 40%-60%, risk stratification by PD-L1 expression and CD8+ lymphocyte infiltration seems to be very powerful. Recently, a correlation between the expression of PD-L1 and the prognosis was demonstrated in mouse models of medulloblastoma. 16 Further combined analysis of the expressions of PD-L1 and CD8 in these models will be worthwhile to confirm our result.
Medulloblastoma has recently been recognized as a heterogeneous disease that can be divided into 4 subtypes according to genetic architecture: Wnt, SHH, Group 3, and Group 4.
3, 19 The prognosis of patients with medulloblastoma differs among these genetic subtypes. The Wnt subtype shows the most favorable prognosis among these subtypes, rendering a 5-year survival rate of 90%. Group 3 medulloblastoma, whose hallmark is MYC amplification, is the most aggressive subtype, showing a 5-year survival rate of 40%-60%. Other subtypes have an intermediate prognosis, with a 5-year survival rate of approximately 75%. It is therefore suspected that PD-L1 expression was different between these molecular subtypes, and that high PD-L1 expression with low CD8 cell infiltration might be more frequently observed in Group 3 medulloblastomas; however, we could not find such correlations. The PD-L1 protein level in tumor samples from patients with glioblastoma has been reported to be correlated with PTEN loss. 15 Similarly, genetic alterations in medulloblastoma may have influence on PD-L1 expression. Recently, a combination of genetic markers was shown to improve prognostic risk stratification for medulloblastoma. 19 In the SHH subtype, GLI2 amplification was associated with worse survival. In the Group 3 subtype (MYC amplification), isochromosome of 17q was associated with worse survival. Thus, MYC or GLI2, a genetic indicator for poor prognosis, might have influence on PD-L1 expression. Although it is difficult to test this assumption in our small study population, further study is necessary to see the relationship between PD-L1 expression and the gene signature of medulloblastoma.
Anti-PD-L1 antibody has emerged as an effective immunotherapy that is effective in various kinds of cancer by inducing potent antitumor immune responses. 8, 17, 20, 24 Because high expression of PD-L1 and reduced infiltration of cytotoxic lymphocytes were associated with poor prognosis in medulloblastoma, anti-PD-L1 blocking antibody could be a potential treatment option for patients with medulloblastoma, especially for those with poor prognosis. On the other hand, mutation-targeted treatments for specific subtypes of medulloblastoma have been studied in preclinical and clinical trials. 10 The Smoothened (SMO) inhibitor for SHH subtypes with the SMO mutation is currently being tested in clinical trials. 3 Bromo and extra C-terminal (BET) bromodomain inhibitors, which interfere with MYC-associated transcriptional activity, were reported to be effective in suppressing the growth of medulloblastoma cells with MYC amplification in vitro and in vivo. 1, 22 Because there is no established treatment for aggressive medulloblastoma, and radiotherapy for young children can cause cognitive impairment, the development of such multiple treatment modalities, including immunotherapy, is essential to improve the prognosis of patients with medulloblastoma.
There is a limitation in our study. Because the number of patients in the study population is small, we could not perform reliable multivariate analysis in which covariates such as Ki-67 index, Chang's criteria, chemotherapy regimens, and radiation dosage were used. Besides, because the recruitment period of the study population was long (> 22 years), changes of diagnostic and treatment modalities might affect the prognosis of the patients. Because we have a small proportion of adult cases, the statistical power was not sufficient. Further large studies are needed to confirm our results.
Conclusions
Upregulation of PD-L1 expression with a reduced CD8+ lymphocyte infiltration was significantly associated with dismal prognosis in patients with medulloblastoma, and anti-PD-L1 antibody may be a potential treatment option for such a subgroup of patients. A larger study is necessary to confirm our results and to analyze the association between genetic signature and PD-L1 expression.
